Volitionrx LTD (VNRX) — 8-K Filings

8-K Filings (20)

• VolitionRx Ltd. Faces Delisting Concerns — Apr 23, 2026 Risk: high
  VolitionRx Ltd. filed an 8-K on April 23, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing also incl
• VolitionRx Relocates HQ, Adjusts Fiscal Year End — Dec 11, 2025 Risk: low
  VolitionRx Limited announced on December 5, 2025, a change in its principal executive offices to 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014
• 8-K Filing — Nov 7, 2025
• VolitionRx Ltd Enters Material Agreement, Reports Financials — Oct 14, 2025 Risk: medium
  VolitionRx Limited (VNRX) announced on October 10, 2025, that it has entered into a material definitive agreement. The company also reported its results of oper
• VolitionRx Limited Files Current Report (8-K) — Aug 4, 2025 Risk: low
  On August 1, 2025, VolitionRx Limited entered into a material definitive agreement. The company, previously known as Standard Capital Corp until August 12, 1999
• VolitionRx Files 8-K: Bylaws, Shareholder Votes, Financials — Jun 20, 2025 Risk: low
  VolitionRx Limited filed an 8-K on June 20, 2025, reporting events as of June 18, 2025. The filing indicates amendments to articles of incorporation or bylaws,
• VolitionRx Ltd. Enters and Terminates Material Agreements — Apr 22, 2025 Risk: medium
  On April 22, 2025, VolitionRx Limited entered into a material definitive agreement and also terminated a material definitive agreement. The company, incorporate
• VolitionRx Files 8-K for Regulation FD Disclosure — Apr 4, 2025 Risk: low
  VolitionRx Limited filed an 8-K on April 4, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material event
• VolitionRx Limited Files 8-K: Material Agreement & Other Events — Mar 26, 2025 Risk: medium
  On March 24, 2025, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company als
• VolitionRx Limited Files 8-K with Material Agreement — Dec 9, 2024 Risk: medium
  On December 5, 2024, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company a
• VolitionRx Appoints New CMO, Elects Director — Nov 6, 2024 Risk: medium
  VolitionRx Limited announced on November 6, 2024, the appointment of Dr. Michael J. O'Sullivan as Chief Medical Officer and the election of Ms. Sarah E. Johnson
• VolitionRx Ltd Files 8-K on Officer/Director Changes — Sep 30, 2024 Risk: low
  VolitionRx Limited filed an 8-K on September 30, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment o
• VolitionRx Ltd. Announces Board and Compensation Changes — Sep 27, 2024 Risk: medium
  VolitionRx Limited announced on September 26, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company electe
• VolitionRx to Acquire BioCheck for $10M — Sep 16, 2024 Risk: medium
  VolitionRx Limited announced on September 16, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of BioChe
• VolitionRx Limited Files 8-K — Aug 12, 2024 Risk: medium
  On August 8, 2024, VolitionRx Limited entered into a material definitive agreement, the details of which are not fully disclosed in this filing but are indicate
• VolitionRx Ltd. Announces Board and Officer Changes — Jul 3, 2024 Risk: medium
  VolitionRx Limited announced on July 2, 2024, a significant change in its corporate structure and leadership. The company filed an 8-K detailing the election of
• VolitionRx Limited Files 8-K Report — Jun 27, 2024 Risk: low
  On June 27, 2024, VolitionRx Limited filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure
• VolitionRx Appoints New CSO, Board Member — Apr 26, 2024 Risk: medium
  VolitionRx Limited announced on April 24, 2024, a change in its board of directors, with the appointment of Dr. David E. Bearss as Chief Scientific Officer and
• VolitionRx to Acquire Private Diagnostics Company — Mar 19, 2024 Risk: medium
  VolitionRx Limited announced on March 19, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of a privatel
• VolitionRx 8-K: Administrative Update, NYSE American Listing Confirmed — Jan 2, 2024
  VolitionRx Limited filed an 8-K on January 2, 2024, reporting an "Other Events" item from December 29, 2023. This filing primarily updates administrative inform

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX